News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
214,145 Results
Type
Article (7651)
Company Profile (38)
Press Release (206456)
Section
Business (56434)
Career Advice (219)
Deals (10785)
Drug Delivery (47)
Drug Development (12742)
Employer Resources (45)
FDA (5864)
Job Trends (5447)
News (88435)
Policy (8765)
Tag
2024 BioCapital Digital (1)
2024 BioMidwest Digital (2)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (1)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
Academia (737)
Adcomms (1)
Allergies (31)
Alliances (15582)
ALS (11)
Alzheimer's disease (332)
Antibody-drug conjugate (ADC) (22)
Approvals (5917)
Artificial intelligence (149)
Autoimmune disease (5)
Automation (3)
Bankruptcy (67)
Best Places to Work (4949)
BIOSECURE Act (4)
Biosimilars (52)
Biotechnology (20)
Bladder cancer (21)
Brain cancer (4)
Breast cancer (84)
Cancer (529)
Cardiovascular disease (61)
Career advice (202)
Career pathing (2)
CAR-T (24)
Cell therapy (90)
Cervical cancer (6)
Clinical research (10820)
Collaboration (283)
Compensation (25)
Complete response letters (2)
COVID-19 (746)
CRISPR (11)
C-suite (89)
Cystic fibrosis (19)
Data (602)
Decentralized trials (1)
Denatured (10)
Depression (11)
Diabetes (85)
Diagnostics (3237)
Digital health (12)
Diversity (3)
Diversity, equity & inclusion (13)
Drug discovery (33)
Drug pricing (46)
Drug shortages (6)
Duchenne muscular dystrophy (30)
Earnings (18048)
Editorial (15)
Employer branding (2)
Employer resources (40)
Events (48377)
Executive appointments (272)
FDA (6305)
Featured Employer (10)
Frontotemporal dementia (3)
Funding (262)
Gene editing (27)
Generative AI (17)
Gene therapy (69)
GLP-1 (175)
Government (1367)
Grass and pollen (2)
Guidances (26)
Healthcare (8731)
Huntington's disease (2)
IgA nephropathy (9)
Immunology and inflammation (21)
Indications (11)
Infectious disease (793)
Inflammatory bowel disease (39)
Inflation Reduction Act (5)
Influenza (12)
Intellectual property (20)
Interviews (22)
IPO (4355)
IRA (16)
Job creations (728)
Job search strategy (188)
Kidney cancer (1)
Labor market (5)
Layoffs (76)
Legal (1672)
Liver cancer (16)
Lung cancer (74)
Lymphoma (34)
Machine learning (1)
Management (19)
Manufacturing (78)
MASH (19)
Medical device (6210)
Medtech (6210)
Mergers & acquisitions (6674)
Metabolic disorders (218)
Multiple sclerosis (31)
NASH (5)
Neurodegenerative disease (18)
Neuropsychiatric disorders (6)
Neuroscience (448)
NextGen: Class of 2025 (2948)
Non-profit (1574)
Northern California (748)
Now hiring (2)
Obesity (119)
Opinion (70)
Ovarian cancer (14)
Pain (19)
Pancreatic cancer (13)
Parkinson's disease (22)
Partnered (8)
Patents (40)
Patient recruitment (30)
Peanut (19)
People (18819)
Pharmaceutical (12)
Pharmacy benefit managers (8)
Phase I (2307)
Phase II (3799)
Phase III (5176)
Pipeline (329)
Podcasts (25)
Policy (42)
Postmarket research (737)
Preclinical (745)
Press Release (11)
Prostate cancer (35)
Psychedelics (6)
Radiopharmaceuticals (77)
Rare diseases (101)
Real estate (1434)
Recruiting (16)
Regulatory (6374)
Reports (16)
Research institute (647)
Resumes & cover letters (20)
Rett syndrome (2)
RSV (15)
Schizophrenia (18)
Series A (41)
Series B (36)
Service/supplier (3)
Sickle cell disease (26)
Southern California (620)
Special edition (6)
Spinal muscular atrophy (35)
Sponsored (6)
Startups (1269)
Stomach cancer (3)
Supply chain (22)
The Weekly (15)
United States (7334)
Vaccines (151)
Venture capitalists (16)
Webinars (4)
Weight loss (61)
Women's health (20)
Worklife (3)
Date
Today (44)
Last 7 days (186)
Last 30 days (912)
Last 365 days (12085)
2025 (3227)
2024 (12221)
2023 (13337)
2022 (20481)
2021 (21869)
2020 (21226)
2019 (18117)
2018 (13344)
2017 (9161)
2016 (9761)
2015 (11227)
2014 (8296)
2013 (6813)
2012 (7112)
2011 (7099)
2010 (5710)
Location
Africa (239)
Alabama (13)
Alaska (1)
Arizona (65)
Arkansas (6)
Asia (11229)
Australia (1505)
California (1666)
Canada (606)
China (160)
Colorado (114)
Connecticut (108)
Delaware (44)
Europe (26913)
Florida (299)
Georgia (91)
Hawaii (1)
Idaho (19)
Illinois (208)
India (17)
Indiana (136)
Iowa (1)
Japan (72)
Kansas (23)
Kentucky (13)
Louisiana (6)
Maine (26)
Maryland (222)
Massachusetts (1359)
Michigan (89)
Minnesota (127)
Mississippi (2)
Missouri (52)
Montana (5)
Nebraska (13)
Nevada (15)
New Hampshire (25)
New Jersey (639)
New Mexico (9)
New York (573)
North Carolina (389)
North Dakota (1)
Northern California (748)
Ohio (64)
Oklahoma (8)
Oregon (11)
Pennsylvania (478)
Puerto Rico (3)
Rhode Island (8)
South America (320)
South Carolina (8)
Southern California (620)
Tennessee (65)
Texas (235)
Utah (97)
Virginia (39)
Washington D.C. (25)
Washington State (140)
West Virginia (3)
Wisconsin (25)
214,145 Results for "quantum leap healthcare".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Evinova and Quantum Leap Healthcare Partner to Incorporate Real-Time Remote Patient Monitoring into Breast Cancer Platform Trial
March 20, 2025
·
3 min read
Press Releases
Esphera SynBio Announces New Project to Advance Next Generation mRNA Vaccine Development, supported by the CQDM Quantum Leap program
January 10, 2025
·
2 min read
Press Releases
Quantum BioPharma Provides Corporate Update
March 31, 2025
·
4 min read
Press Releases
IonQ Reaches Important Milestone in Achieving Faster Quantum Gates for Quantum Computing and Networking
March 5, 2025
·
6 min read
Drug Development
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer.
October 30, 2023
·
6 min read
Press Releases
Quantum BioPharma Unaware of Any Material Change
March 17, 2025
·
1 min read
Press Releases
Quantum BioPharma Provides Corporate Update
March 10, 2025
·
8 min read
Business
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial.
June 28, 2023
·
6 min read
Biotech Bay
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex’s oral paclitaxel plus encequidar in combination with GSK’s dostarlimab in the neoadjuvant setting at this year’s American Society of Clinical Oncology (ASCO) conference.
May 1, 2023
·
4 min read
Biotech Bay
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.
May 2, 2023
·
7 min read
1 of 21,415
Next
